The treatment of infections caused by carbapenem-resistant Enterobacterales, especially New Delhi metallo-β-lactamase (NDM)-producing bacteria, is challenging. Although less common in the United States than some other carbapenemase producers, NDM-producing bacteria are a public health threat due to the limited treatment options available. Here, we report on the antibiotic susceptibility of 275 contemporary NDM-producing Enterobacterales collected from 30 U.S. states through the Centers for Disease Control and Prevention’s Antibiotic Resistance Laboratory Network. The aims of the study were to determine the susceptibility of these isolates to 32 currently available antibiotics using reference broth microdilution and to explore the in vitro activity of 3 combination agents that are not yet available. Categorical interpretations were determined using Clinical and Laboratory Standards Institute (CLSI) interpretive criteria. For agents without CLSI criteria, Food and Drug Administration (FDA) interpretive criteria were used. The percentage of susceptible isolates did not exceed 90% for any of the FDA-approved antibiotics tested. The antibiotics with breakpoints that had the highest in vitro activity were tigecycline (86.5% susceptible), eravacycline (66.2% susceptible), and omadacycline (59.6% susceptible); 18.2% of isolates were susceptible to aztreonam. All NDM-producing isolates tested were multidrug resistant, and 116 isolates were extensively drug resistant (42.2%); 207 (75.3%) isolates displayed difficult-to-treat resistance. The difficulty in treating infections caused by NDM-producing Enterobacterales highlights the need for containment and prevention efforts to keep these infections from becoming more common.


Carbapenem-resistant Enterobacterales (CRE) are an urgent public health threat (1). In 2017, CRE caused an estimated 13,100 cases in hospitalized patients, 1,100 deaths, and $130 million in estimated attributable health care costs in the United States (1). Carbapenem resistance in Enterobacterales can develop via several mechanisms, the most concerning of which is the presence of carbapenemases. Carbapenemases are often carried on mobile genetic elements that can spread easily between bacteria (2). Treatment options for these infections are limited, and mortality associated with CRE infections is higher than for carbapenem-susceptible Enterobacterales infections (3, 4). Since 2015, newly available β-lactam combination agents such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam have shown promise in treating CRE infections, especially with CRE that produce the Klebsiella pneumoniae carbapenemase (KPC) (57). However, none of these newer β-lactam combination agents exhibit significant activity against the metallo-β-lactamases (MBLs), including the New Delhi MBL (NDM) (8).
Since the initial reports of NDM in 2009, NDM-producing CRE have disseminated worldwide, and they are endemic in India, Pakistan, and Bangladesh (911). Isolates with blaNDM were found in the United States in specimens collected as early as 2009 (11). Since then, the detection of carbapenemase-producing CRE has been facilitated by the establishment of the Antibiotic Resistance Laboratory Network (AR Lab Network) (https://www.cdc.gov/drugresistance/solutions-initiative/ar-lab-networks.html). Established in 2016, the AR Lab Network is composed of 55 public health laboratories across the United States with the aim to rapidly detect and contain antibiotic resistance. A report of the first nine months of testing in the AR Lab Network revealed that 3.2% of CRE tested were positive for blaNDM (12). Thus, while NDM appeared to be the most common MBL in the United States, Verona integron-encoded MBL (VIM) and active-on-imipenem MBL (IMP) were also found to be present in 0.3% and 0.4% of Enterobacterales, respectively (12). Data on the percentage of CRE isolates that were positive for MBLs in the AR Lab Network during 2017 and 2018 are now available (https://arpsp.cdc.gov/profile/antibiotic?tab=ar-lab-network). The emergence of MBL-producing isolates is a concerning development, as these isolates are especially resistant to antibiotics, including the newer β-lactam combination agents, and have displayed pan-resistance (13).
In this study, we sought to determine the antimicrobial susceptibility testing (AST) results for NDM-producing Enterobacterales in the United States against a set of 32 currently available antibiotics and 3 combination agents that are not yet available. To accomplish this, we requested NDM-positive isolates tested by the AR Lab Network between January 2017 and November 2018. These data will help inform clinicians, public health authorities, and policy makers about possible treatment options for infections caused by NDM-producing Enterobacterales.


A total of 275 unique Enterobacterales isolates carrying blaNDM collected through November 2018 were submitted from 30 AR Lab Network laboratories to the Centers for Disease Control and Prevention (CDC). Isolates were sent from all seven regions of the AR Lab Network (https://www.cdc.gov/drugresistance/laboratories/AR-lab-network-testing-details.html): West (n = 67), Northeast (n = 59), Midwest (n = 44), Southeast (n = 33), Mountain (n = 31), Mid-Atlantic (n = 28), and Central (n = 13). The isolates comprised eight different species, including 125 Klebsiella pneumoniae, 115 Escherichia coli, 28 Enterobacter cloacae complex, 3 Proteus mirabilis, 1 Citrobacter freundii, 1 Klebsiella aerogenes, 1 Klebsiella oxytoca, and 1 Providencia stuartii isolate. The isolates were recovered from a diverse range of primary specimens, including blood (n = 29), respiratory (n = 11), stool or rectal swab (n = 45), urine (n = 144), and other (n = 46) specimens.
All isolates were confirmed to harbor blaNDM. The modified carbapenem inactivation method (mCIM) was positive for carbapenemase production in all isolates. The broth microdilution (BMD) metallo-β-lactamase screen was positive for 270 isolates (98.2%), negative for 4 isolates (1.5%), and indeterminate for 1 isolate (0.4%).
All isolates were resistant to ertapenem, cefoxitin, cefotaxime, ceftriaxone, ceftazidime, ampicillin, ampicillin-sulbactam, and ceftolozane-tazobactam using Clinical and Laboratory Standards Institute (CLSI) interpretive criteria (14). The MIC ranges, MIC50, MIC90, and categorical interpretations for the remaining drugs are shown in Table 1. No more than 18.2% of isolates were susceptible to any β-lactam or fluoroquinolone (Table 1). Isolate susceptibilities to aminoglycosides, tetracyclines, trimethoprim-sulfamethoxazole, chloramphenicol, and nitrofurantoin varied (Table 1). Nitrofurantoin data were similar for isolates from urinary sources and the overall isolate set (Table 1). For colistin, 99.1% of E. coli isolates, 92.8% of K. pneumoniae isolates, and 96.4% of E. cloacae complex isolates were wild type (WT) based on a CLSI-established epidemiological cutoff value of ≤2 μg/ml (14). All quality control results were within approved ranges (14).
TABLE 1 In vitro activities of antibiotics tested against Enterobacterales with blaNDM collected in the United States from January 2017 to November 2018
Organism(s) (n) and drugaMIC (μg/ml)CLSI interpretive criteria
RangeMIC50MIC90% Sb% Ic% Rd
All Enterobacterales (275)      
    Doripenem1 to >8>8>80.42.996.7
    Imipenem2 to >6416640.02.997.1
    Meropenem0.5 to >8>8>81.81.896.4
    Cefepimee8 to >32>32>320.00.799.3
    Piperacillin-tazobactam16/4 to >128/4>128/4>128/40.70.798.5
    Aztreonam<2 to >64>64>6418.21.880.0
    Ceftazidime-avibactam<0.5/4 to >16/4>16/4>16/40.7NAf99.3
    Imipenem-relebactam2/4 to >64/48/432/40.02.597.5
    Meropenem-vaborbactam<0.5/8 to >16/816/8>16/810.217.172.7
    Aztreonam-avibactam<0.03/4 to 32/40.25/44/4NANANA
    Cefepime-taniborbactam0.12/4 to >64/42/432/4NANANA
    Cefepime-zidebactam0.06/0.06 to >64/640.25/0.254/4NANANA
    Ciprofloxacin<0.25 to >8>8>85.82.591.6
    Levofloxacin<0.12 to >8>8>89.84.485.8
    Amikacin<1 to >6416>6452.70.746.5
    Gentamicin<0.25 to >16>16>1632.01.866.2
    Plazomicin0.12 to >1282>12852.71.545.8
    Tobramycin<0.5 to >16>16>1620.05.574.5
    Eravacycline0.12 to >40.5266.2NANA
    Minocycline<4 to >168>1648.416.435.3
    Omadacycline0.5 to >3243259.618.921.5
    Tetracycline<2 to >32>32>3235.66.957.5
    Tigecycline<0.5 to >4<0.5486.58.45.1
    Trimethoprim-sulfamethoxazole<0.5/8.5 to >8/152>8/152>8/15220.7NA79.3
    Chloramphenicol<2 to >16>16>1624.022.253.8
    Nitrofurantoing<16 to >12864>12835.316.448.4
    Nitrofurantoinh (n = 144)<16 to >12864>12845.112.542.4
    Colistin<0.25 to >80.51NANANA
Escherichia coli (115)      
    Doripenem1 to >8>8>80.92.696.5
    Imipenem2 to 648160.02.697.4
    Meropenem0.5 to >8>8>81.70.997.4
    Cefepime16 to >32>32>320.00.0100.0
    Piperacillin-tazobactam128/4 to >128/4>128/4>128/40.00.0100.0
    Aztreonam<2 to >64>64>6415.71.782.6
    Ceftazidime-avibactam<0.5/4 to >16/4>16/4>16/40.9NA99.1
    Imipenem-relebactam2/4 to 64/48/416/40.01.798.3
    Meropenem-vaborbactam<0.5/8 to >16/8>16/8>16/86.117.476.5
    Aztreonam-avibactam<0.03/4 to 32/42/48/4NANANA
    Cefepime-taniborbactam0.12/4 to >64/48/432/4NANANA
    Cefepime-zidebactam0.06/0.06 to 4/40.12/0.120.5/0.5NANANA
    Ciprofloxacin<0.25 to >8>8>
    Levofloxacin<0.12 to >8>8>85.21.793.0
    Amikacin<1 to >648>6459.10.040.9
    Gentamicin<0.25 to >16>16>1639.11.759.1
    Plazomicin0.25 to >1282>12856.51.741.7
    Tobramycin<0.5 to >16>16>1632.22.665.2
    Eravacycline0.12 to 40.5187.0NANA
    Minocycline<4 to >16<4>1653.013.033.9
    Omadacycline0.5 to 322886.19.64.3
    Tetracycline<2 to >32>32>3225.20.973.9
    Tigecycline<0.5 to 2<0.5<0.5100.00.00.0
    Trimethoprim-sulfamethoxazole<0.5/8.5 to >8/152>8/152>8/15215.7NA84.3
    Chloramphenicol<2 to >1616>1632.434.339.1
    Nitrofurantoin<16 to >128<1612877.411.311.3
    Nitrofurantoinh (n = 78)<16 to >128<1612876.911.511.5
    Colistin0.5 to 40.51NANANA
Klebsiella pneumoniae (125)      
    Doripenem2 to >8>8>80.00.899.2
    Imipenem2 to >6416640.00.899.2
    Meropenem1 to >8>8>80.81.697.6
    Cefepime16 to >32>32>320.00.0100.0
    Aztreonam<2 to >64>64>6421.62.476.0
    Ceftazidime-avibactam2/4 to >16/4>16/4>16/40.8NA99.2
    Imipenem-relebactam2/4 to >64/416/464/40.02.497.6
    Meropenem-vaborbactam1/8 to >16/816/8>16/810.416.872.8
    Aztreonam-avibactam<0.03/4 to 4/40.25/40.5/4NANANA
    Cefepime-taniborbactam0.12/4 to >64/41/432/4NANANA
    Cefepime-zidebactam0.06/0.06 to >64/640.5/0.54/4NANANA
    Ciprofloxacin<0.25 to >8>8>
    Levofloxacin<0.12 to >8>8>88.05.686.4
    Amikacin<1 to >64>64>6440.80.858.4
    Gentamicin<0.25 to >16>16>1624.02.473.6
    Plazomicin0.12 to >128>128>12843.20.856.0
    Tobramycin<0.5 to >16>16>168.04.887.2
    Eravacycline0.25 to >40.5451.2NANA
    Minocycline<4 to >168>1644.821.633.6
    Omadacycline1 to >3283239.228.032.8
    Tetracycline<2 to >328>3244.813.641.6
    Tigecycline<0.5 to >41479.214.46.4
    Trimethoprim-sulfamethoxazole<0.5/8.5 to >8/152>8/152>8/15224.0NA76.0
    Chloramphenicol<2 to >16>16>1619.216.864.0
    Nitrofurantoin<16 to >128>128>1284.016.879.2
    Nitrofurantoinh (n = 51)<16 to >128>128>1283.911.884.3
    Colistin<0.25 to >80.51NANANA
Categorical interpretation was determined according to CLSI document M100-S29 when available (14). Imipenem-relebactam, plazomicin, eravacycline, omadacycline, and tigecycline categorical interpretation was determined by FDA interpretive criteria (15).
S, susceptible.
I, intermediate.
R, resistant.
Cefepime does not have an intermediate category but has a susceptible-dose-dependent category (14).
NA, not applicable (no breakpoint available for this category or drug).
Categorical interpretation applies only to organisms from urine (14).
Reported for isolates originating from urine cultures.
All 275 isolates were multidrug resistant (MDR), and 116 (42.2%) were extensively drug resistant (XDR) (34.8% of E. coli and 46.4% of K. pneumoniae isolates); 207 (75.3%) isolates displayed difficult-to-treat resistance (80.9% of E. coli and 76.0% of K. pneumoniae isolates). Thirteen isolates (4.7%) were categorized as pan-not susceptible (intermediate or resistant) to all 31 drugs with CLSI or FDA breakpoints (14, 15). Four of these 13 isolates (30.8%) also displayed a non-wild-type colistin MIC of ≥4 μg/ml. Three isolates (1.1%) displayed resistance to all 31 drugs and were categorized as pan-resistant; one of these also showed a colistin non-wild-type MIC.
MIC ranges and MIC50 and MIC90 values for aztreonam-avibactam, cefepime-taniborbactam, and cefepime-zidebactam, which are not FDA approved, are provided in Table 1 (16). There were 23 isolates (8.4%) with an aztreonam-avibactam MIC of >4/4 μg/ml and 8 isolates (2.9%) with an aztreonam-avibactam MIC of >8/4 μg/ml. There were 80 isolates (29.1%) with a cefepime-taniborbactam MIC of >8/4 μg/ml, and there were 8 isolates (2.9%) with a cefepime-zidebactam MIC of >8/8 μg/ml.


This report describes the AST results of 275 Enterobacterales isolates harboring blaNDM collected in the United States during 2017 and 2018. The high proportion of resistance to all currently FDA-approved antibiotics highlights the difficulty clinicians face when attempting to treat infections caused by NDM-producing Enterobacterales. The proportion of susceptible isolates did not exceed 90% for any of the FDA-approved antibiotics tested.
β-Lactams and fluoroquinolones are considered the first-line agents for the treatment of serious Gram-negative infections (17). In this collection, the proportion of isolates with resistance to these agents was very high. Aztreonam showed the highest in vitro activity of all FDA-approved β-lactams, with 18.2% of isolates displaying susceptibility. This was expected, as aztreonam is not hydrolyzed by NDM but is by extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases; thus, the high number of isolates that were not susceptible to aztreonam likely represents the coproduction of other β-lactamases in addition to NDM. Similar levels of aztreonam activity against NDM-producing bacteria have been described by others (18, 19).
Aminoglycosides are not considered first-line agents due to their potential to cause nephrotoxicity, but their use has been advocated for the treatment of CRE infections (20). A newer agent, plazomicin, has been demonstrated to be superior to colistin for the treatment of infections caused by CRE (21). In the present evaluation, plazomicin and amikacin demonstrated similar activities, as both drugs generated susceptible results for 52.7% of the NDM-producing isolates tested. The observed susceptibility to plazomicin was lower than reported from a recent study in which 66% of NDM-positive isolates were susceptible to plazomicin (22). In previous studies, resistance to plazomicin has been attributed to 16S rRNA methylases that confer high-level resistance to all aminoglycosides, including reported plasmids that harbor both blaNDM and 16S rRNA methylase genes (11, 23, 24). In our study, none of the aminoglycosides tested showed reliable activity against NDM-producing bacteria; nevertheless, these agents may have a role to play in the treatment of some of these infections when AST is performed and susceptibility is confirmed.
Eravacycline was approved by the FDA in August 2018 for the treatment of complicated intra-abdominal infections. Eravacycline and tigecycline exhibited similar MIC50 and MIC90 values for this collection of isolates. The higher susceptibility observed with tigecycline than with eravacycline is due to the different breakpoints (≤0.5 μg/ml is susceptible for eravacycline and ≤2 μg/ml is susceptible for tigecycline) established by FDA. Neither agent has CLSI breakpoints, and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint for tigecycline is lower than the FDA breakpoint (≤0.5 μg/ml is susceptible per EUCAST and ≤2 μg/ml is susceptible per the FDA) (15, 25). Using the more conservative EUCAST breakpoints, 61.8% and 66.2% of the NDM-producing isolates would be categorized as susceptible to tigecycline and eravacycline, respectively. Regardless of the breakpoints applied, these two drugs displayed the highest in vitro activities of all FDA-approved antibiotics tested in this study. However, limitations exist for both drugs. A pooling of tigecycline noninferiority studies demonstrated that tigecycline was associated with excess deaths compared with other drugs (26). Also, tigecycline only has FDA-approved indications for complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia (27). It has proven inferior to comparator antibiotics for ventilator-associated pneumonia and urinary tract infections (27, 28). Eravacycline is currently indicated only for the treatment of complicated intra-abdominal infections and is not indicated for the treatment of complicated urinary tract infections (8).
Omadacycline was approved by the FDA in October 2018 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; 59.6% of the isolates in this study were susceptible to omadacycline. This agent may have a role in the treatment of some infections with NDM-producing bacteria when AST is performed and susceptibility is confirmed.
Colistin, which has been suggested as a treatment option for CRE (20), displayed in vitro activity against the NDM producers in this collection; 94.5% of isolates tested had a colistin wild-type MIC. Nonetheless, colistin has consistently been found to be inferior to other active agents for the treatment of CRE, so its role in the treatment of NDM producers remains to be determined (5, 21, 28). In addition to questionable efficacy, colistin treatment is associated with high rates of nephrotoxicity and performing colistin AST is problematic (20, 29). Colistin disk AST and gradient diffusion AST are unreliable, leaving broth microdilution, colistin broth disk elution, and the colistin agar test as the only reliable methods of testing (29, 30).
Nitrofurantoin lacks a role in the treatment of serious invasive infections due to its limited systemic absorption, but it may be useful in the treatment of uncomplicated urinary tract infections (31). Among all E. coli isolates with blaNDM in this collection, 77.4% displayed susceptibility to nitrofurantoin; thus, it remains an agent with reasonable activity for uncomplicated urinary tract infections. For Enterobacterales isolates other than E. coli, only 5.0% displayed susceptibility.
AST was also performed with some agents that are not FDA approved, namely, cefepime-taniborbactam, cefepime-zidebactam, and aztreonam-avibactam. Testing with cefepime-taniborbactam and cefepime-zidebactam resulted in MICs severalfold lower than for cefepime alone. The activity of cefepime-zidebactam against metallo-β-lactamase producers has been described previously by Sader et al., who found the MIC50 and MIC90 to be 0.5/0.5 and 8/8 μg/ml, respectively, for 20 MBL-producing strains (32). Importantly, no clinical breakpoints currently exist for these investigational agents; thus, MIC results cannot be construed to infer susceptibility or potential clinical utility.
Aztreonam-avibactam is intriguing, as it can currently be administered to patients by combining two FDA-approved drugs, aztreonam and ceftazidime-avibactam. There are several case reports documenting the use of ceftazidime-avibactam with aztreonam (3335). Clinical trials will be needed to confirm the efficacy of this combination. In our study, the MIC90 of aztreonam-avibactam for all isolates tested was 4/4 μg/ml, although higher MICs were associated with the E. coli than the K. pneumoniae isolates (MIC90 of 8/4 μg/ml and MIC90 of 0.5/4 μg/ml, respectively). For clinicians considering the combination of ceftazidime-avibactam and aztreonam for patients with highly resistant infections caused by Enterobacterales, AST for aztreonam-avibactam is available through the AR Lab Network’s Expanded Antimicrobial Susceptibility Testing for Hard-to-Treat Infections (ExAST) program (https://www.cdc.gov/drugresistance/laboratories/ar-lab-network-testing-details/expanded-ast.html). Caution should be exercised when interpreting MIC results since no clinical breakpoints have been established.
One limitation of this study is that the AST profiles presented may not be representative of all NDM-producing isolates in the United States because the isolates tested were a convenience sample. Another limitation is that cefiderocol, which is an FDA-approved agent with activity against NDM-producing Enterobacterales, was not evaluated (36, 37). Lastly, whole-genome sequence analysis would be required to determine the genetic relatedness of the isolates and the complete set of acquired resistance determinants present. Strengths of this study include both the large number of contemporaneous isolates with a rare resistance mechanism collected from geographically diverse regions in the United States and the large number of antibiotics tested, including almost all currently available therapeutic options. Caution should be exercised when interpreting the results for the non-FDA-approved drug combinations given that no clinical efficacy data are available and clinical breakpoints have not been established. Pharmacokinetic and pharmacodynamic data also remain unknown for these non-FDA-approved combinations. Further research would be necessary to determine the genetic explanation for the observed MIC values. Future research could also explore fosfomycin AST, which must be performed by agar dilution, and cefiderocol AST by broth microdilution, which requires a special formulation of iron-depleted cation-adjusted Mueller-Hinton broth (14).
In summary, NDM-producing Enterobacterales cause infections that present substantial treatment challenges. The proportion of susceptible isolates did not exceed 90% for any of the FDA-approved antibiotics tested. This study may help inform clinicians of which agents retain the most efficacy against these highly resistant organisms. The difficulty in treating these infections highlights the importance of rapid detection, containment, and infection control efforts to prevent these infections from becoming more common.


In September 2018, the CDC requested that public health laboratories in the AR Lab Network submit all Enterobacterales isolates with blaNDM collected since 1 January 2017. The AR Lab Network includes the public health laboratories of all 50 states, four large cities, and Puerto Rico. Isolates were deduplicated so that only one isolate per species per patient was analyzed. If multiple isolates of the same species were submitted from the same patient, the isolate with the earliest collection date was chosen for inclusion in the study. If multiple isolates of the same species from the same patient were collected on the same day, the most invasive isolate was chosen for inclusion in the study.
Organism identification of all isolates was confirmed by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry using a Biotyper 3.1 MALDI-TOF system (Bruker Daltonics, Billerica, MA). A multiplex PCR was performed on all isolates to confirm the presence of blaNDM and to detect blaKPC (11). The mCIM test was performed on all isolates in accordance with CLSI guidance to confirm that blaNDM was conferring carbapenemase production (14). The BMD metallo-β-lactamase screen, which is an imipenem MIC compared to an imipenem MIC with a fixed concentration of EDTA and 1,10-phenanthroline, was performed on all isolates; an MIC decrease of ≥2 doubling dilutions was considered positive (11, 38).
AST of isolates was performed for 32 FDA-approved antibiotics and 3 combination agents that are not FDA approved using in-house-developed frozen reference BMD panels according to CLSI guidance (39). Panels were prepared using 96-well sterile, U-bottom polystyrene plates (Caplugs, Buffalo, NY) with cation-adjusted Mueller-Hinton broth (BD Difco, Sparks, MD). The inoculum was prepared by adjusting a suspension of isolated colonies from overnight growth in 0.85% saline to a turbidity equivalent to a 0.5 McFarland standard. The panels were inoculated with a 95-pin sterile inoculator (10 μl pickup; Caplugs). E. coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), K. pneumoniae (BAA-2146, ATCC 700603, and BAA-2814), and Acinetobacter baumannii (NCTC 13304) were used for quality control on each day of testing (American Type Culture Collection, Manassas, VA, and National Collection of Type Cultures, London, United Kingdom). In addition, E. coli NCTC 13353 was used as an initial quality control of each lot of cefepime-taniborbactam-containing panels. Aztreonam-avibactam MICs were determined using a fixed concentration of avibactam (4 μg/ml), cefepime-taniborbactam MICs were determined using a fixed concentration of taniborbactam (4 μg/ml), and cefepime-zidebactam MICs were determined using a 1:1 concentration of cefepime to zidebactam. All categorical interpretations were determined according to CLSI guidance (14). When no CLSI guidance was available, FDA interpretive criteria were used (15). AST was performed once for each isolate.
Each isolate was categorized as MDR or XDR according to the criteria described by Magiorakos et al. (40). Briefly, an isolate was defined as MDR if intermediate or resistant to at least one agent in three or more antibiotic categories; an isolate was defined as XDR if intermediate or resistant to at least one agent in all but two or fewer categories. For the purposes of MDR or XDR classification, CLSI interpretive criteria were applied when available; FDA interpretive criteria were applied for tigecycline, and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria were applied for colistin (MIC of ≤2 μg/ml is susceptible and MIC of >2 μg/ml is resistant) (25). Isolates were also categorized as difficult to treat based on the criteria described by Kadri et al. (17). Briefly, difficult-to-treat isolates were defined as isolates that were intermediate or resistant to all β-lactams and fluoroquinolones (excluding recently approved β-lactam combination agents).


The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
This study was performed under General Protocol number 7218 for ethical approval by the Institutional Review Board of the Centers for Disease Control and Prevention. We thank Achaogen, Melinta Therapeutics, Inc., Merck Sharp & Dohme Corp., Paratek Pharmaceuticals, Inc., Tetraphase Pharmaceuticals, Inc., Venatorx Pharmaceuticals, Inc., and Wockhardt Bio, AG, for supplying the drug powders for plazomicin, vaborbactam, ceftolozane, relebactam, omadacycline, eravacycline, cefepime–VNRX-5133 (now named cefepime-taniborbactam), and zidebactam. We also thank Cipla, USA, Inc. (the current provider of plazomicin).


Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF. 2018. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66:1290–1297.
Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. 2014. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175.
Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. 2017. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 38:1319–1328.
Motsch J, Murta de Oliveira C, Stus V, Kӧksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A. 2020. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 70:1799–1808.
van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. 2018. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 7:439–455.
Wright H, Bonomo RA, Paterson DL. 2017. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect 23:704–712.
Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602.
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054.
Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ, Savard P, Humphries RM, Kallen AJ, Limbago BM. 2013. New Delhi metallo-beta-lactamase-producing Enterobacteriaceae, United States. Emerg Infect Dis 19:870–878.
Woodworth KR, Walters MS, Weiner LM, Edwards J, Brown AC, Huang JY, Malik S, Slayton RB, Paul P, Capers C, Kainer MA, Wilde N, Shugart A, Mahon G, Kallen AJ, Patel J, McDonald LC, Srinivasan A, Craig M, Cardo DM. 2018. Vital Signs: containment of novel multidrug-resistant organisms and resistance mechanisms—United States, 2006–2017. MMWR Morb Mortal Wkly Rep 67:396–401.
de Man TJB, Lutgring JD, Lonsway DR, Anderson KF, Kiehlbauch JA, Chen L, Walters MS, Sjolund-Karlsson M, Rasheed JK, Kallen A, Halpin AL. 2018. Genomic analysis of a pan-resistant isolate of Klebsiella pneumoniae, United States 2016. mBio 9:e00440-18.
Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing; 29th informational supplement. CLSI document M100-S29. Clinical and Laboratory Standards Institute, Wayne, PA.
Food and Drug Administration. 2019. Antibacterial susceptibility test interpretive criteria. https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria. Accessed 27 November 2019.
Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM. 2020. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 64:e01963-19.
Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH, Suffredini AF, Hooper DC, Fridkin S, Danner RL, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI). 2018. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 67:1803–1814.
Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. 2016. Multiyear, multinational survey of the incidence and global distribution of metallo-beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067–1078.
Jain A, Hopkins L, Turton J, Doumith M, Hill R, Loy R, Meunier D, Pike R, Livermore DM, Woodford N. 2014. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. J Antimicrob Chemother 69:1777–1784.
Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. 2015. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2:ofv050.
McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, Care Study Group. 2019. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med 380:791–793.
Serio AW, Keepers T, Krause KM. 2019. Plazomicin is active against metallo-beta-lactamase-producing Enterobacteriaceae. Open Forum Infect Dis 6:ofz123.
Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. 2018. In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother 62:e00313-18.
Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48–53.
European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0, valid from 2019-01-01. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf. Accessed 27 November 2019.
Prasad P, Sun J, Danner RL, Natanson C. 2012. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699–1709.
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. 2011. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55:5893–5899.
Humphries RM. 2015. Susceptibility testing of the polymyxins: where are we now? Pharmacotherapy 35:22–27.
Humphries RM, Green DA, Schuetz AN, Bergman Y, Lewis S, Yee R, Stump S, Lopez M, Macesic N, Uhlemann AC, Kohner P, Cole N, Simner PJ. 2019. Multicenter evaluation of colistin broth disk elution and colistin agar test: a report from the Clinical and Laboratory Standards Institute. J Clin Microbiol 57:e01269-19.
Gupta K, Hooton TM, Stamm WE. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135:41–50.
Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M. 2017. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant beta-lactamases. J Antimicrob Chemother 72:1696–1703.
Falcone M, Tiseo G, Antonelli A, Giordano C, Di Pilato V, Bertolucci P, Parisio EM, Leonildi A, Aiezza N, Baccani I, Tagliaferri E, Righi L, Forni S, Sani S, Mechi MT, Pieralli F, Barnini S, Rossolini GM, Menichetti F. 2020. Clinical features and outcomes of bloodstream infections caused by New Delhi metallo-beta-lactamase-producing Enterobacterales during a regional outbreak. Open Forum Infect Dis 7:ofaa011.
Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16.
Shaw E, Rombauts A, Tubau F, Padullés A, Càmara J, Lozano T, Cobo-Sacristán S, Sabe N, Grau I, Rigo-Bonnin R, Dominguez MA, Carratalà J. 2018. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 73:1104–1106.
Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, Domitrovic TN, Rudin SD, Richter SS, van Duin D, Kreiswirth BN, Greco C, Fouts DE, Bonomo RA. 2019. ARGONAUT-1: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β-lactamases and carbapenemases. Antimicrob Agents Chemother 63:e01801-18.
Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734.
Migliavacca R, Docquier JD, Mugnaioli C, Amicosante G, Daturi R, Lee K, Rossolini GM, Pagani L. 2002. Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa. J Clin Microbiol 40:4388–4390.
Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th edition. CLSI document M07-11. Clinical and Laboratory Standards Institute, Wayne, PA.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281.

Information & Contributors


Published In

cover image Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Volume 64Number 920 August 2020
eLocator: 10.1128/aac.00499-20


Received: 13 March 2020
Returned for modification: 17 May 2020
Accepted: 7 June 2020
Published online: 20 August 2020


Request permissions for this article.


  1. antibiotic resistance
  2. carbapenems
  3. Enterobacterales
  4. NDM



Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Rocío Balbuena
Goldbelt C6, LLC, Juneau, Alaska, USA
Natashia Reese
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Sarah E. Gilbert
Goldbelt C6, LLC, Juneau, Alaska, USA
Uzma Ansari
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Amelia Bhatnagar
Goldbelt C6, LLC, Juneau, Alaska, USA
Sandra Boyd
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Davina Campbell
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Jake Cochran
Goldbelt C6, LLC, Juneau, Alaska, USA
Jenn Haynie
Goldbelt C6, LLC, Juneau, Alaska, USA
Justina Ilutsik
Goldbelt C6, LLC, Juneau, Alaska, USA
Cynthia Longo
Goldbelt C6, LLC, Juneau, Alaska, USA
Stephanie Swint
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
J. Kamile Rasheed
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Allison C. Brown
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA


Address correspondence to Joseph D. Lutgring, [email protected].

Metrics & Citations


Note: There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.

Citation counts come from the Crossref Cited by service.


If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

View Options

Figures and Media






Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy